Previous close | 0.4000 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 15.00 |
Expiry date | 2024-07-19 |
Day's range | 0.4000 - 0.4000 |
Contract range | N/A |
Volume | |
Open interest | 161 |
PALO ALTO, Calif., May 23, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock.
PALO ALTO, Calif., May 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
PALO ALTO, Calif., May 21, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced certification for its Guardant360® CDx blood test under the European Union’s In Vitro Diagnostic Regulation (IVDR 2017/746). The certification from TÜV SÜD Product Service is for tumor mutation profiling in patients with any solid cancerous tumor and for companion diagnostic indications to identify patients who may benefit from certain targeted therapies for advanced non-sma